Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE)
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
A multi-centre, randomized, placebo controlled, trial. Participants at high-risk for vascular
events from the network of INTER- CHF will be randomized to inactivated influenza vaccine or
placebo and followed prospectively over three influenza seasons. 5,000 participants will be
enrolled prior to influenza season, randomized to either influenza vaccine or saline placebo,
either of which they will receive annually for three years and then followed over each of the
influenza seasons.